Portfolio Holdings Detail for ISIN IE00BDZVHG35
Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /var/www/liquidata/show_ticker_holding_ETFs.php on line 67
Stock Name / Fund iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)
Issuer Blackrock

ETF Ticker BTEE(USD) LSE
ETF Ticker BTEE.L(GBP) LSE

Holdings detail for ASND

Stock Name	Ascendis Pharma AS
Ticker	ASND(USD) NASDAQ
TYPE	Common Stock
Country	USA
ISIN	US04351P1012
LEI	549300B66JN3W3J8GH73

Show aggregate ASND holdings

News associated with ASND

Ascendis Pharma A/S (NASDAQ:ASND) Receives $244.36 Average PT from Analysts: Shares of Ascendis Pharma A/S (NASDAQ:ASND – Get Free Report) have been given a consensus rating of “Buy” by the fifteen analysts that are covering the stock, Marketbeat Ratings reports. Fifteen investment analysts have rated the stock with a buy recommendation. The average 12 month price objective among analysts that have updated their coverage on […] - 2025-09-19 02:58:53
Ascendis Pharma A/S (NASDAQ:ASND) Cut to “Hold” at Wall Street Zen: Wall Street Zen lowered shares of Ascendis Pharma A/S (NASDAQ:ASND – Free Report) from a buy rating to a hold rating in a report issued on Friday morning. A number of other brokerages have also recently issued reports on ASND. JPMorgan Chase & Co. upped their price objective on shares of Ascendis Pharma A/S from […] - 2025-09-08 02:54:56
Ascendis Pharma A/S (NASDAQ:ASND) Sets New 1-Year High Following Analyst Upgrade: Ascendis Pharma A/S (NASDAQ:ASND – Get Free Report) shares reached a new 52-week high during trading on Tuesday after Bank of America raised their price target on the stock from $227.00 to $230.00. Bank of America currently has a buy rating on the stock. Ascendis Pharma A/S traded as high as $202.79 and last traded […] - 2025-09-04 02:20:48
Ascendis Pharma A/S (NASDAQ:ASND) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says: Ascendis Pharma A/S (NASDAQ:ASND – Free Report) had its price target upped by JPMorgan Chase & Co. from $254.00 to $260.00 in a research note released on Tuesday,Benzinga reports. The brokerage currently has an overweight rating on the biotechnology company’s stock. A number of other research firms also recently commented on ASND. UBS Group reaffirmed […] - 2025-08-20 03:10:54
Ascendis Pharma A/S (NASDAQ:ASND) Sets New 1-Year High After Analyst Upgrade: Ascendis Pharma A/S (NASDAQ:ASND – Get Free Report) shares reached a new 52-week high during trading on Monday after Wall Street Zen upgraded the stock from a hold rating to a buy rating. The stock traded as high as $199.99 and last traded at $193.57, with a volume of 1554046 shares changing hands. The stock […] - 2025-08-13 02:17:08
Ascendis Pharma A/S (NASDAQ:ASND) Stock Price Expected to Rise, Royal Bank Of Canada Analyst Says: Ascendis Pharma A/S (NASDAQ:ASND – Free Report) had its price objective increased by Royal Bank Of Canada from $210.00 to $230.00 in a research report report published on Friday morning,Benzinga reports. The firm currently has an outperform rating on the biotechnology company’s stock. A number of other brokerages have also weighed in on ASND. UBS […] - 2025-08-11 03:58:55
Ascendis Pharma A/S (NASDAQ:ASND) Price Target Raised to $254.00: Ascendis Pharma A/S (NASDAQ:ASND – Free Report) had its target price raised by Stifel Nicolaus from $212.00 to $254.00 in a research report released on Friday morning,Benzinga reports. They currently have a buy rating on the biotechnology company’s stock. Several other brokerages have also issued reports on ASND. Royal Bank Of Canada boosted their price […] - 2025-08-11 03:58:52
Ascendis Pharma A/S (NASDAQ:ASND) Given New $307.00 Price Target at UBS Group: Ascendis Pharma A/S (NASDAQ:ASND – Free Report) had its price objective lifted by UBS Group from $306.00 to $307.00 in a research note released on Friday morning,Benzinga reports. The brokerage currently has a buy rating on the biotechnology company’s stock. Other equities research analysts have also issued reports about the stock. JPMorgan Chase & Co. […] - 2025-08-11 03:58:52
Wedbush Forecasts Strong Price Appreciation for Ascendis Pharma A/S (NASDAQ:ASND) Stock: Ascendis Pharma A/S (NASDAQ:ASND – Free Report) had its price objective boosted by Wedbush from $212.00 to $220.00 in a research note issued to investors on Friday,Benzinga reports. Wedbush currently has an outperform rating on the biotechnology company’s stock. A number of other research analysts also recently commented on the stock. Evercore ISI boosted their […] - 2025-08-11 03:58:51
Ascendis Pharma A/S (NASDAQ:ASND) Raised to Buy at Wall Street Zen: Ascendis Pharma A/S (NASDAQ:ASND – Get Free Report) was upgraded by equities researchers at Wall Street Zen from a “hold” rating to a “buy” rating in a research note issued to investors on Saturday. ASND has been the topic of several other reports. JPMorgan Chase & Co. upped their price objective on Ascendis Pharma A/S […] - 2025-08-11 03:58:51
Citigroup Forecasts Strong Price Appreciation for Ascendis Pharma A/S (NASDAQ:ASND) Stock: Ascendis Pharma A/S (NASDAQ:ASND – Free Report) had its target price hoisted by Citigroup from $243.00 to $290.00 in a research note published on Friday morning,Benzinga reports. They currently have a buy rating on the biotechnology company’s stock. ASND has been the topic of several other reports. Stifel Nicolaus raised their target price on shares […] - 2025-08-11 03:58:51
CGGR's Underlying Holdings Imply 10% Gain Potential: Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-08-07 09:07:36
XTX Topco Ltd Buys New Shares in Ascendis Pharma A/S (NASDAQ:ASND): XTX Topco Ltd bought a new position in shares of Ascendis Pharma A/S (NASDAQ:ASND – Free Report) during the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 3,746 shares of the biotechnology company’s stock, valued at approximately $584,000. Several other institutional investors and hedge […] - 2025-08-06 05:20:59
Ascendis Pharma A/S (NASDAQ:ASND) Receives $223.07 Average PT from Analysts: Shares of Ascendis Pharma A/S (NASDAQ:ASND – Get Free Report) have earned an average recommendation of “Buy” from the fifteen ratings firms that are covering the firm, Marketbeat.com reports. Fifteen analysts have rated the stock with a buy rating. The average 12 month target price among brokerages that have covered the stock in the last […] - 2025-07-31 03:13:06
Ascendis Pharma A/S (NASDAQ:ASND) Price Target Raised to $254.00 at JPMorgan Chase & Co.: Ascendis Pharma A/S (NASDAQ:ASND – Free Report) had its price target increased by JPMorgan Chase & Co. from $245.00 to $254.00 in a research note released on Tuesday,Benzinga reports. They currently have an overweight rating on the biotechnology company’s stock. ASND has been the subject of a number of other research reports. Cantor Fitzgerald reiterated […] - 2025-07-30 04:34:56
Ascendis Pharma Says FDA Approves SKYTROFA For Adults With Growth Hormone Deficiency: (RTTNews) - Swiss biopharmaceutical company Ascendis Pharma A/S (ASND) announced Monday that the U.S. Food & Drug Administration (FDA) has approved SKYTROFA (lonapegsomatropin-tcgd; developed as TransCon hGH) for the replacement of endogenous growth hormone in adults with growth - 2025-07-28 08:40:00
Victory Capital Management Inc. Cuts Holdings in Ascendis Pharma A/S (NASDAQ:ASND): Victory Capital Management Inc. lessened its stake in Ascendis Pharma A/S (NASDAQ:ASND – Free Report) by 4.9% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 124,926 shares of the biotechnology company’s stock after selling 6,427 shares during the […] - 2025-07-23 06:00:57
Sigma Planning Corp Purchases Shares of 1,515 Ascendis Pharma A/S (NASDAQ:ASND): Sigma Planning Corp bought a new stake in shares of Ascendis Pharma A/S (NASDAQ:ASND – Free Report) in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 1,515 shares of the biotechnology company’s stock, valued at approximately $236,000. A […] - 2025-07-22 07:24:51
Morgan Stanley Initiates Coverage on Ascendis Pharma A/S (NASDAQ:ASND): Morgan Stanley began coverage on shares of Ascendis Pharma A/S (NASDAQ:ASND – Free Report) in a report published on Thursday morning, Marketbeat Ratings reports. The brokerage issued an overweight rating and a $250.00 price target on the biotechnology company’s stock. A number of other analysts have also recently issued reports on ASND. Wedbush boosted their […] - 2025-07-04 04:59:43
Ascendis Pharma A/S (NASDAQ:ASND) Price Target Raised to $224.00: Ascendis Pharma A/S (NASDAQ:ASND – Free Report) had its target price hoisted by Oppenheimer from $215.00 to $224.00 in a research report sent to investors on Friday morning,Benzinga reports. They currently have an outperform rating on the biotechnology company’s stock. ASND has been the topic of several other reports. Bank of America increased their target […] - 2025-06-16 02:50:47
Analysts Set Ascendis Pharma A/S (NASDAQ:ASND) Price Target at $216.73: Shares of Ascendis Pharma A/S (NASDAQ:ASND – Get Free Report) have earned an average rating of “Buy” from the fifteen brokerages that are covering the stock, Marketbeat Ratings reports. Fifteen equities research analysts have rated the stock with a buy rating. The average 1 year target price among brokers that have covered the stock in […] - 2025-06-11 04:54:50
Bank of America Forecasts Strong Price Appreciation for Ascendis Pharma A/S (NASDAQ:ASND) Stock: Ascendis Pharma A/S (NASDAQ:ASND – Get Free Report) had its price target hoisted by Bank of America from $201.00 to $216.00 in a report released on Monday,Benzinga reports. The brokerage currently has a “buy” rating on the biotechnology company’s stock. Bank of America‘s price target suggests a potential upside of 25.33% from the company’s current […] - 2025-06-11 02:44:49
Two Sigma Investments LP Cuts Holdings in Ascendis Pharma A/S (NASDAQ:ASND): Two Sigma Investments LP decreased its stake in shares of Ascendis Pharma A/S (NASDAQ:ASND – Free Report) by 78.2% during the 4th quarter, Holdings Channel.com reports. The firm owned 10,915 shares of the biotechnology company’s stock after selling 39,173 shares during the period. Two Sigma Investments LP’s holdings in Ascendis Pharma A/S were worth $1,503,000 […] - 2025-06-04 05:08:54
Nuveen Asset Management LLC Sells 170 Shares of Ascendis Pharma A/S (NASDAQ:ASND): Nuveen Asset Management LLC lessened its holdings in Ascendis Pharma A/S (NASDAQ:ASND – Free Report) by 1.2% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 14,430 shares of the biotechnology company’s stock after selling 170 shares during the period. Nuveen Asset Management LLC’s holdings in Ascendis Pharma A/S were worth $1,987,000 as of […] - 2025-06-04 04:36:50
Two Sigma Advisers LP Has $743,000 Stock Holdings in Ascendis Pharma A/S (NASDAQ:ASND): Two Sigma Advisers LP cut its holdings in Ascendis Pharma A/S (NASDAQ:ASND – Free Report) by 88.6% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 5,400 shares of the biotechnology company’s stock after selling 41,858 shares during the quarter. Two Sigma Advisers […] - 2025-06-03 05:00:51
ProShare Advisors LLC Reduces Holdings in Ascendis Pharma A/S (NASDAQ:ASND): ProShare Advisors LLC reduced its holdings in shares of Ascendis Pharma A/S (NASDAQ:ASND – Free Report) by 16.6% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,857 shares of the biotechnology company’s stock after selling 567 shares during the quarter. ProShare Advisors […] - 2025-05-28 04:54:54
Tower Research Capital LLC TRC Boosts Stake in Ascendis Pharma A/S (NASDAQ:ASND): Tower Research Capital LLC TRC grew its position in Ascendis Pharma A/S (NASDAQ:ASND – Free Report) by 195.3% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 1,004 shares of the biotechnology company’s stock after purchasing an additional 664 shares during the period. Tower Research Capital […] - 2025-05-08 05:08:53
Ascendis Pharma A/S (NASDAQ:ASND) Upgraded at Morgan Stanley: Ascendis Pharma A/S (NASDAQ:ASND – Get Free Report) was upgraded by research analysts at Morgan Stanley from an “equal weight” rating to an “overweight” rating in a research note issued to investors on Monday, MarketBeat reports. The firm presently has a $250.00 price objective on the biotechnology company’s stock, up from their previous price objective […] - 2025-05-07 02:58:50
LPL Financial LLC Increases Position in Ascendis Pharma A/S (NASDAQ:ASND): LPL Financial LLC increased its position in shares of Ascendis Pharma A/S (NASDAQ:ASND – Free Report) by 60.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,199 shares of the biotechnology company’s stock after acquiring an additional 1,577 shares […] - 2025-04-24 04:54:46
Analysts Set Ascendis Pharma A/S (NASDAQ:ASND) Target Price at $204.67: Shares of Ascendis Pharma A/S (NASDAQ:ASND – Get Free Report) have earned an average recommendation of “Moderate Buy” from the fifteen ratings firms that are presently covering the stock, MarketBeat reports. One research analyst has rated the stock with a hold rating and fourteen have given a buy rating to the company. The average 12-month […] - 2025-04-22 03:04:57

iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) ASND holdings

Date	Number of ASND Shares Held	Base Market Value of ASND Shares	Local Market Value of ASND Shares	Change in ASND Shares Held	Change in ASND Base Value	Current Price per ASND Share Held	Previous Price per ASND Share Held
2026-01-15 (Thursday)	42,109	USD 9,055,119	USD 9,055,119	192	USD -54,283	USD 215.04	USD 217.32
2026-01-14 (Wednesday)	41,917	USD 9,109,402	USD 9,109,402	192	USD 136,441	USD 217.32	USD 215.05
2026-01-13 (Tuesday)	41,725	USD 8,972,961	USD 8,972,961	0	USD 262,450	USD 215.05	USD 208.76
2026-01-12 (Monday)	41,725	USD 8,710,511	USD 8,710,511	192	USD 279,727	USD 208.76	USD 202.99
2026-01-09 (Friday)	41,533	USD 8,430,784	USD 8,430,784	288	USD -179,110	USD 202.99	USD 208.75
2026-01-08 (Thursday)	41,245	USD 8,609,894	USD 8,609,894	0	USD -186,840	USD 208.75	USD 213.28
2026-01-07 (Wednesday)	41,245	USD 8,796,734	USD 8,796,734	192	USD 204,752	USD 213.28	USD 209.29
2026-01-06 (Tuesday)	41,053	USD 8,591,982	USD 8,591,982	0	USD -158,465	USD 209.29	USD 213.15
2026-01-05 (Monday)	41,053	USD 8,750,447	USD 8,750,447	0	USD -5,747	USD 213.15	USD 213.29
2026-01-02 (Friday)	41,053	USD 8,756,194	USD 8,756,194	96	USD 22,523	USD 213.29	USD 213.24
2025-12-31 (Wednesday)	40,957	USD 8,733,671	USD 8,733,671	0	USD 159,733	USD 213.24	USD 209.34

Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of ASND by Blackrock for IE00BDZVHG35

Show aggregate share trades of ASND

Date Action Quantity Market High Market Low Likely Trade Price Likely Trade Value (Profit/Loss) Average Price previous trades
2026-01-15 BUY 192 219.000 213.495 214.045 USD 41,097 168.52
2026-01-14 BUY 192 219.760 211.000 211.876 USD 40,680 168.31
2026-01-12 BUY 192 211.410 188.080 190.413 USD 36,559 167.93
2026-01-09 BUY 288 213.810 201.130 202.398 USD 58,291 167.77
2026-01-07 BUY 192 219.270 209.180 210.189 USD 40,356 167.39
2026-01-02 BUY 96 215.980 210.760 211.282 USD 20,283 166.79
2025-12-30 BUY 96 213.870 208.020 208.605 USD 20,026 166.39
2025-12-23 SELL -1,140 212.900 205.730 206.447 USD -235,350 165.57 Loss of -46,595 on sale
2025-12-19 SELL -2,981 202.610 197.155 197.700 USD -589,345 165.21 Loss of -96,853 on sale
2025-12-17 SELL -510 212.072 202.090 203.088 USD -103,575 164.87 Loss of -19,491 on sale
2025-12-16 SELL -102 212.560 204.520 205.324 USD -20,943 164.65 Loss of -4,149 on sale
2025-12-15 BUY 204 221.638 212.470 213.387 USD 43,531 164.42
2025-12-11 BUY 522 218.880 201.644 203.367 USD 106,158 163.93
2025-12-04 BUY 2,040 209.450 198.600 199.685 USD 407,357 162.95
2025-12-03 BUY 243 204.500 198.330 198.947 USD 48,344 162.77
2025-12-02 BUY 1,515 212.248 200.410 201.594 USD 305,415 162.57
2025-11-28 BUY 101 214.790 209.000 209.579 USD 21,167 162.08
2025-11-26 BUY 303 218.500 207.600 208.690 USD 63,233 161.60
2025-11-26 BUY 303 218.500 207.600 208.690 USD 63,233 161.60
2025-11-25 BUY 505 213.455 203.020 204.064 USD 103,052 161.37
2025-11-24 BUY 101 217.320 208.420 209.310 USD 21,140 161.13
2025-11-20 SELL -404 214.220 208.760 209.306 USD -84,560 160.62 Loss of -19,667 on sale
2025-11-19 BUY 101 217.730 208.010 208.982 USD 21,107 160.36
2025-11-18 BUY 606 222.957 214.020 214.914 USD 130,238 160.06
2025-11-17 BUY 202 223.155 202.500 204.565 USD 41,322 159.77
2025-11-14 BUY 101 219.300 202.770 204.423 USD 20,647 159.53
2025-11-12 BUY 101 205.000 198.260 198.934 USD 20,092 159.07
2025-11-10 BUY 101 201.000 195.825 196.342 USD 19,831 158.65
2025-11-06 BUY 101 200.550 196.950 197.310 USD 19,928 158.21
2025-11-04 BUY 101 208.410 197.600 198.681 USD 20,067 157.72
2025-10-30 BUY 505 206.885 203.030 203.415 USD 102,725 156.98
2025-10-29 BUY 202 205.710 208.390 208.122 USD 42,041 156.70
2025-10-22 SELL -404 202.700 204.960 204.734 USD -82,713 155.37 Loss of -19,945 on sale
2025-10-20 BUY 202 205.210 212.980 212.203 USD 42,865 154.81
2025-10-17 BUY 505 210.500 214.470 214.073 USD 108,107 154.48
2025-10-15 BUY 808 207.120 212.480 211.944 USD 171,251 154.17
2025-10-03 BUY 700 204.050 205.160 205.049 USD 143,534 153.54
2025-10-02 BUY 100 200.970 204.125 203.810 USD 20,381 153.26
2025-09-30 BUY 200 198.810 199.980 199.863 USD 39,973 152.67
2025-09-26 BUY 200 191.990 192.020 192.017 USD 38,403 152.19
2025-09-25 BUY 200 189.740 192.450 192.179 USD 38,436 151.96
2025-09-18 BUY 104 199.370 200.415 200.310 USD 20,832 151.66
2025-09-17 BUY 315 199.590 200.550 200.454 USD 63,143 151.36
2025-07-17 SELL -210 177.200 177.930 177.857 USD -37,350 150.67 Loss of -5,710 on sale
2025-07-16 BUY 344 175.400 176.230 176.147 USD 60,595 150.51
2025-07-11 SELL -832 174.960 177.180 176.958 USD -147,229 150.02 Loss of -22,410 on sale
2025-07-02 BUY 5,720 173.100 174.335 174.212 USD 996,490 149.35
2025-06-25 BUY 208 173.000 179.200 178.580 USD 37,145 148.69
2025-06-20 BUY 856 176.900 177.210 177.179 USD 151,665 148.08
2025-06-13 BUY 160 170.800 173.820 173.518 USD 27,763 147.17
2025-06-11 BUY 200 171.720 174.108 173.869 USD 34,774 146.81
2025-06-10 BUY 200 172.350 175.350 175.050 USD 35,010 146.62
2025-06-04 SELL -100 173.690 177.970 177.542 USD -17,754 145.75 Loss of -3,179 on sale
2025-04-23 BUY 100 158.140 161.875 161.501 USD 16,150 140.63
2025-04-10 SELL -800 143.330 146.930 146.570 USD -117,256 138.98 Loss of -6,073 on sale
2025-04-08 SELL -100 137.410 146.440 145.537 USD -14,554 139.01 Loss of -653 on sale
2025-04-07 SELL -100 140.140 143.640 143.290 USD -14,329 139.00 Loss of -429 on sale
2025-04-04 SELL -500 142.670 147.490 147.008 USD -73,504 138.95 Loss of -4,027 on sale
2025-04-01 BUY 871 151.430 158.450 157.748 USD 137,399 138.64
2025-03-31 SELL -297 155.860 156.960 156.850 USD -46,584 138.43 Loss of -5,469 on sale
2025-03-21 BUY 1,324 165.990 168.400 168.159 USD 222,643 136.65
2025-03-14 SELL -1,504 152.980 155.390 155.149 USD -233,344 134.79 Loss of -30,622 on sale
2025-03-07 SELL -188 145.740 152.410 151.743 USD -28,528 133.91 Loss of -3,353 on sale
2025-03-04 SELL -94 150.810 152.330 152.178 USD -14,305 133.01 Loss of -1,802 on sale
2025-02-25 BUY 188 151.530 152.780 152.655 USD 28,699 131.27
2025-02-19 SELL -94 155.110 156.690 156.532 USD -14,714 129.64 Loss of -2,528 on sale
2025-02-13 BUY 282 142.490 147.680 147.161 USD 41,499 128.28
2025-02-12 BUY 94 126.140 127.620 127.472 USD 11,982 128.32
2025-02-11 BUY 376 119.510 120.580 120.473 USD 45,298 128.50
2024-12-30 SELL -2,069 136.480 138.470 138.271 USD -286,083 128.94 Loss of -19,311 on sale
2024-11-18 SELL -1,485 122.000 127.340 126.806 USD -188,307 127.15 Profit of 517 on sale
2024-11-08 SELL -99 124.330 128.200 127.813 USD -12,653 127.32 Loss of -49 on sale
2024-10-21 SELL -99 128.660 130.660 130.460 USD -12,916 0.00 Loss of -12,916 on sale
Market high and low price is on the date.

Date	Action	Quantity	Market High	Market Low	Likely Trade Price	Likely Trade Value (Profit/Loss)	Average Price previous trades
2026-01-15	BUY	192	219.000	213.495	214.045	USD 41,097	168.52
2026-01-14	BUY	192	219.760	211.000	211.876	USD 40,680	168.31
2026-01-12	BUY	192	211.410	188.080	190.413	USD 36,559	167.93
2026-01-09	BUY	288	213.810	201.130	202.398	USD 58,291	167.77
2026-01-07	BUY	192	219.270	209.180	210.189	USD 40,356	167.39
2026-01-02	BUY	96	215.980	210.760	211.282	USD 20,283	166.79
2025-12-30	BUY	96	213.870	208.020	208.605	USD 20,026	166.39
2025-12-23	SELL	-1,140	212.900	205.730	206.447	USD -235,350	165.57 Loss of -46,595 on sale
2025-12-19	SELL	-2,981	202.610	197.155	197.700	USD -589,345	165.21 Loss of -96,853 on sale
2025-12-17	SELL	-510	212.072	202.090	203.088	USD -103,575	164.87 Loss of -19,491 on sale
2025-12-16	SELL	-102	212.560	204.520	205.324	USD -20,943	164.65 Loss of -4,149 on sale
2025-12-15	BUY	204	221.638	212.470	213.387	USD 43,531	164.42
2025-12-11	BUY	522	218.880	201.644	203.367	USD 106,158	163.93
2025-12-04	BUY	2,040	209.450	198.600	199.685	USD 407,357	162.95
2025-12-03	BUY	243	204.500	198.330	198.947	USD 48,344	162.77
2025-12-02	BUY	1,515	212.248	200.410	201.594	USD 305,415	162.57
2025-11-28	BUY	101	214.790	209.000	209.579	USD 21,167	162.08
2025-11-26	BUY	303	218.500	207.600	208.690	USD 63,233	161.60
2025-11-26	BUY	303	218.500	207.600	208.690	USD 63,233	161.60
2025-11-25	BUY	505	213.455	203.020	204.064	USD 103,052	161.37
2025-11-24	BUY	101	217.320	208.420	209.310	USD 21,140	161.13
2025-11-20	SELL	-404	214.220	208.760	209.306	USD -84,560	160.62 Loss of -19,667 on sale
2025-11-19	BUY	101	217.730	208.010	208.982	USD 21,107	160.36
2025-11-18	BUY	606	222.957	214.020	214.914	USD 130,238	160.06
2025-11-17	BUY	202	223.155	202.500	204.565	USD 41,322	159.77
2025-11-14	BUY	101	219.300	202.770	204.423	USD 20,647	159.53
2025-11-12	BUY	101	205.000	198.260	198.934	USD 20,092	159.07
2025-11-10	BUY	101	201.000	195.825	196.342	USD 19,831	158.65
2025-11-06	BUY	101	200.550	196.950	197.310	USD 19,928	158.21
2025-11-04	BUY	101	208.410	197.600	198.681	USD 20,067	157.72
2025-10-30	BUY	505	206.885	203.030	203.415	USD 102,725	156.98
2025-10-29	BUY	202	205.710	208.390	208.122	USD 42,041	156.70
2025-10-22	SELL	-404	202.700	204.960	204.734	USD -82,713	155.37 Loss of -19,945 on sale
2025-10-20	BUY	202	205.210	212.980	212.203	USD 42,865	154.81
2025-10-17	BUY	505	210.500	214.470	214.073	USD 108,107	154.48
2025-10-15	BUY	808	207.120	212.480	211.944	USD 171,251	154.17
2025-10-03	BUY	700	204.050	205.160	205.049	USD 143,534	153.54
2025-10-02	BUY	100	200.970	204.125	203.810	USD 20,381	153.26
2025-09-30	BUY	200	198.810	199.980	199.863	USD 39,973	152.67
2025-09-26	BUY	200	191.990	192.020	192.017	USD 38,403	152.19
2025-09-25	BUY	200	189.740	192.450	192.179	USD 38,436	151.96
2025-09-18	BUY	104	199.370	200.415	200.310	USD 20,832	151.66
2025-09-17	BUY	315	199.590	200.550	200.454	USD 63,143	151.36
2025-07-17	SELL	-210	177.200	177.930	177.857	USD -37,350	150.67 Loss of -5,710 on sale
2025-07-16	BUY	344	175.400	176.230	176.147	USD 60,595	150.51
2025-07-11	SELL	-832	174.960	177.180	176.958	USD -147,229	150.02 Loss of -22,410 on sale
2025-07-02	BUY	5,720	173.100	174.335	174.212	USD 996,490	149.35
2025-06-25	BUY	208	173.000	179.200	178.580	USD 37,145	148.69
2025-06-20	BUY	856	176.900	177.210	177.179	USD 151,665	148.08
2025-06-13	BUY	160	170.800	173.820	173.518	USD 27,763	147.17
2025-06-11	BUY	200	171.720	174.108	173.869	USD 34,774	146.81
2025-06-10	BUY	200	172.350	175.350	175.050	USD 35,010	146.62
2025-06-04	SELL	-100	173.690	177.970	177.542	USD -17,754	145.75 Loss of -3,179 on sale
2025-04-23	BUY	100	158.140	161.875	161.501	USD 16,150	140.63
2025-04-10	SELL	-800	143.330	146.930	146.570	USD -117,256	138.98 Loss of -6,073 on sale
2025-04-08	SELL	-100	137.410	146.440	145.537	USD -14,554	139.01 Loss of -653 on sale
2025-04-07	SELL	-100	140.140	143.640	143.290	USD -14,329	139.00 Loss of -429 on sale
2025-04-04	SELL	-500	142.670	147.490	147.008	USD -73,504	138.95 Loss of -4,027 on sale
2025-04-01	BUY	871	151.430	158.450	157.748	USD 137,399	138.64
2025-03-31	SELL	-297	155.860	156.960	156.850	USD -46,584	138.43 Loss of -5,469 on sale
2025-03-21	BUY	1,324	165.990	168.400	168.159	USD 222,643	136.65
2025-03-14	SELL	-1,504	152.980	155.390	155.149	USD -233,344	134.79 Loss of -30,622 on sale
2025-03-07	SELL	-188	145.740	152.410	151.743	USD -28,528	133.91 Loss of -3,353 on sale
2025-03-04	SELL	-94	150.810	152.330	152.178	USD -14,305	133.01 Loss of -1,802 on sale
2025-02-25	BUY	188	151.530	152.780	152.655	USD 28,699	131.27
2025-02-19	SELL	-94	155.110	156.690	156.532	USD -14,714	129.64 Loss of -2,528 on sale
2025-02-13	BUY	282	142.490	147.680	147.161	USD 41,499	128.28
2025-02-12	BUY	94	126.140	127.620	127.472	USD 11,982	128.32
2025-02-11	BUY	376	119.510	120.580	120.473	USD 45,298	128.50
2024-12-30	SELL	-2,069	136.480	138.470	138.271	USD -286,083	128.94 Loss of -19,311 on sale
2024-11-18	SELL	-1,485	122.000	127.340	126.806	USD -188,307	127.15 Profit of 517 on sale
2024-11-08	SELL	-99	124.330	128.200	127.813	USD -12,653	127.32 Loss of -49 on sale
2024-10-21	SELL	-99	128.660	130.660	130.460	USD -12,916	0.00 Loss of -12,916 on sale

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of ASND

Date	Shorted Volume	Short Exempt Volume	Total Shares Traded	% Shorted
2025-09-19	121,748	6,400	179,053	68.0%
2025-09-18	35,114	0	59,068	59.4%
2025-09-17	58,718	10	109,051	53.8%
2025-09-16	50,547	0	103,264	48.9%
2025-09-15	45,485	0	81,865	55.6%
2025-09-12	49,729	0	102,985	48.3%
2025-09-11	64,066	0	158,849	40.3%
2025-09-10	58,788	0	242,952	24.2%
2025-09-09	38,790	0	119,195	32.5%
2025-09-08	110,464	11	192,296	57.4%
2025-09-05	128,647	6,400	268,849	47.9%
2025-09-04	50,558	0	123,304	41.0%
2025-09-03	57,923	2,277	189,313	30.6%
2025-09-02	85,172	0	241,590	35.3%
2025-08-29	56,548	3,456	129,201	43.8%
2025-08-28	49,022	0	179,374	27.3%
2025-08-27	51,035	0	170,324	30.0%
2025-08-26	28,659	0	87,205	32.9%
2025-08-25	55,738	0	143,979	38.7%
2025-08-22	66,448	0	157,164	42.3%
2025-08-21	53,383	0	178,303	29.9%
2025-08-20	47,592	0	174,277	27.3%
2025-08-19	50,748	0	165,115	30.7%
2025-08-18	44,303	0	370,345	12.0%
2025-08-15	51,406	0	101,097	50.8%
2025-08-14	58,744	0	173,228	33.9%
2025-08-13	86,518	5,446	289,310	29.9%
2025-08-12	331,120	0	451,980	73.3%
2025-08-11	115,577	31	200,963	57.5%
2025-08-08	379,312	762	747,420	50.7%
2025-08-07	189,347	0	343,785	55.1%
2025-08-06	87,885	0	162,647	54.0%
2025-08-05	129,631	0	283,397	45.7%
2025-08-04	121,053	0	196,498	61.6%
2025-08-01	57,635	0	106,208	54.3%
2025-07-31	164,688	0	285,489	57.7%
2025-07-30	105,105	0	211,067	49.8%
2025-07-29	73,869	0	140,327	52.6%
2025-07-28	81,940	0	148,590	55.1%
2025-07-25	119,180	0	197,342	60.4%
2025-07-24	113,114	0	262,843	43.0%
2025-07-23	124,992	0	236,110	52.9%
2025-07-22	53,127	0	112,666	47.2%
2025-07-21	86,388	0	116,122	74.4%
2025-07-18	183,720	0	311,132	59.0%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Note: All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability.

Stock Name / Fund	iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)
Issuer	Blackrock
ETF Ticker	BTEE(USD) LSE
ETF Ticker	BTEE.L(GBP) LSE